Rare disease drug development and commercialization for the US market
ITF Therapeutics is the newly launched US rare disease division of Italfarmaco, a 1938-founded global pharma company. The organization is in active hiring mode (12 roles posted in the last 30 days, velocity accelerating) with a distinctly commercial lean: healthcare, marketing, and data roles dominate the department mix, anchored by senior and director-level hires. This staffing pattern and project list—speaker bureaus, advisory boards, market research, customer segmentation—indicate a go-to-market operation still in build phase, paired with core infrastructure (SQL, Python, Tableau, SAS, Salesforce, IQVIA) typical of mid-sized pharma operations.
Notable leadership hires: Business Development Director
ITF Therapeutics was established in January 2024 as Italfarmaco's dedicated US rare disease division. The company focuses on developing and commercializing treatments for rare diseases, with particular expertise signaled in Duchenne muscular dystrophy. Operating from Concord, Massachusetts, with 51–200 employees, the organization brings together clinical development, clinical research, and commercial capabilities to advance products addressing unmet needs in rare disease communities. The team actively engages with patient advocacy groups and treatment leaders to inform program design and ensure alignment with patient and clinical community priorities.
Market research, customer segmentation, speaker bureau programs, advisory board planning, and clinical conference coordination focused on rare diseases. Projects center on go-to-market strategy, awareness training, and field material development.
SQL, Python, Tableau, Power BI, Veeva, Salesforce, IQVIA, SAS, and R. AWS EMR is used for data processing. No major tech migrations or adoptions are currently underway.
Other companies in the same industry, closest in size